| Q28472665 | A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children |
| Q24612084 | Abiraterone in metastatic prostate cancer without previous chemotherapy |
| Q41572870 | Assessment of the Efficacy of New Anti-Tuberculosis Drugs |
| Q36381197 | Bayesian methods for evidence synthesis in cost-effectiveness analysis |
| Q36831404 | Biomarkers of treatment response in clinical trials of novel antituberculosis agents |
| Q30370596 | Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints |
| Q27022171 | Concordance of effects of medical interventions on hospital admission and readmission rates with effects on mortality |
| Q41660829 | Dynamic Optimal Strategy for Monitoring Disease Recurrence |
| Q59356581 | Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals |
| Q61917171 | Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system d |
| Q42026879 | Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project |
| Q34364879 | Markers for nutrition studies: review of criteria for the evaluation of markers |
| Q37458317 | Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. |
| Q36552307 | Progression-free survival as a surrogate endpoint in advanced breast cancer |
| Q33538308 | Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model |
| Q37184783 | Study design issues in evaluating immune biomarkers |
| Q37035523 | The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus |
| Q36255766 | Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. |
| Q36022784 | Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? |